Related Experiment Video

Updated: Oct 1, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

M Milella1, S M Kornblau, Z Estrov

  • 1Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

The Journal of Clinical Investigation
|September 19, 2001
PubMed

Insights

Small-molecule MEK inhibitors significantly impair acute myeloid leukemia (AML) cell growth and survival by blocking the MAPK pathway. This targeted approach shows promise for AML therapy with minimal impact on healthy cells.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • The mitogen-activated protein kinase (MAPK) pathway is crucial for cell growth and survival.
  • Constitutive activation of the MAPK pathway is implicated in various cancers, including acute myeloid leukemia (AML).
  • Targeting aberrant signaling pathways is a key strategy in cancer therapy.

Purpose of the Study:

  • To investigate the efficacy of small-molecule MEK inhibitors in targeting the MAPK pathway in AML.
  • To evaluate the effects of MEK inhibition on leukemic cell growth, survival, and apoptosis.
  • To explore the molecular mechanisms underlying MEK inhibitor action in AML.

Main Methods:

  • Treatment of AML cell lines and primary samples with MEK inhibitors (PD98059 and PD184352).
  • Assessment of cell growth, clonogenicity, and apoptosis induction.
  • Analysis of molecular markers including cyclin-dependent kinase inhibitors and apoptosis-related proteins (IAP, Bcl-2 family).

Main Results:

  • MEK inhibitors profoundly impaired the growth and survival of AML cells with constitutive MAPK activation.
  • These agents abrogated leukemic cell clonogenicity while sparing normal hematopoietic progenitors.
  • MEK blockade sensitized cells to apoptosis and modulated expression of key regulatory proteins (p27Kip1, p21Waf1/CIP1, IAPs, Bcl-2).

Conclusions:

  • Targeting the MEK/MAPK pathway with small-molecule inhibitors is a potent therapeutic strategy for AML.
  • MEK inhibition selectively affects leukemic cells, offering a potential therapeutic window.
  • Modulation of cell cycle and apoptosis regulators underlies the anti-leukemic effects of MEK blockade.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...